European Green Transition founder Cathal Friel joins board as non-exec chair
One of the co-founders of European Green Transition (), Cathal Friel, has joined the company’s board as non-executive chairman.
Friel is a seasoned serial entrepreneur with over 20 years’ experience in corporate finance and M&A. He was previously chair of hVIVO PLC (formerly Open Orphan), where he successfully completed the acquisition and integration of two loss-making businesses, Venn Life Sciences and hVIVO.
Prior to hVIVO, he co-founded Amryt Pharma, which listed on the London Stock Exchange in 2016 and dual listed on Nasdaq in 2020 and was later sold to Chiesi Farmaceutici for US$1.48 billion in 2023.
He is also co-founder and chairman of Poolbeg Pharma, a publicly listed biopharmaceutical company which was demerged from hVIVO plc in 2021. and is Managing Director of Raglan Capital
Friel co-founded EGT in 2021, and has been critical in shaping EGT’s strategy, moving away from exploration and mining to focus EGT on acquiring revenue generating businesses.
The outgoing chairman Daniel Akselson will remain on the board as a non-executive director.
“EGT remains focused on delivering on its M&A strategy, targeting revenue generating businesses that support the green energy transition,” said Friel. “I see huge potential to replicate the successful M&A strategy implemented at hVIVO and EGT is currently in discussions with a number of revenue generating businesses operating in the green economy, and I believe this strategy will transform EGT into a strong, cash-generative and profitable businesses in the future.”
View from Vox
A timely development for European Green Transition, as it looks to monetise its Olserum rare earths project in Scandinavia and capitalise on a number of ongoing opportunities. The experience that Friel brings will prove invaluable, and investors should look forward to some useful newsflow in the months to come.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.